Table 1. Baseline Patient Characteristics.
| Characteristic | Control (n = 24) | Treatment (n = 24) | Valid n (Control) | Valid n (Treatment) |
|---|---|---|---|---|
|
| ||||
| Mean age, years | 58.4 | 50.7 | 24 | 24 |
|
| ||||
| Baseline positive CTCs, no. (%) | 18 (75) | 12 (55) | 24 | 22 |
|
| ||||
| Mean baseline platelet count, k/mm3 | 243.7 | 231.6 | 23 | 23 |
|
| ||||
| Mean ARU | 585.4 | 604.8 | 23 | 20 |
|
| ||||
| Mean baseline clopidogrel platelet function, % platelet inhibition | 11.9 | 10.3 | 24 | 22 |
|
| ||||
| HER2+ no. (%) | 10 (42) | 8 (33) | 24 | 24 |
|
| ||||
| ER+, no. (%) | 13 (54) | 15 (62) | 24 | 24 |
|
| ||||
| Number of metastatic sites, no. (%) | – | – | 24 | 24 |
|
| ||||
| 1 | 9 (38) | 8 (33) | – | – |
|
| ||||
| 2 | 7 (29) | 7 (29) | ||
|
| ||||
| ≥ 3 | 8 (33) | 9 (38) | ||
|
| ||||
| Number of previous metastatic chemotherapy regimens, no. (%) | – | – | 24 | 24 |
|
| ||||
| 0 | 4 (17) | 6 (25) | – | – |
|
| ||||
| 1 | 8 (33) | 5 (21) | – | – |
|
| ||||
| 2 | 6 (25) | 4 (17) | – | – |
|
| ||||
| ≥ 3 | 6 (25) | 9 (37) | – | – |
|
| ||||
| Number of previous metastatic endocrine therapies, no. (%) | – | – | 24 | 24 |
|
| ||||
| 0 | 11 (46) | 8 (33) | – | – |
|
| ||||
| 1 | 3 (12) | 7 (29) | – | – |
|
| ||||
| ≥ 2 | 10 (42) | 9 (38) | – | – |
|
| ||||
| Concurrent trastuzumab use, no. (%) | 9 (38) | 5 (21) | 24 | 24 |
|
| ||||
| Concurrent bisphosphonate use, no. (%) | 9 (38) | 12 (50) | 24 | 24 |
|
| ||||
| Smoking, no. (%) | 5 (22) | 4 (17) | 23 | 23 |
Abbreviations: ARU = aspirin reaction units; ER = estrogen receptor; HER = human epidermal growth factor.